• Align Technology recently filed a Section 337 complaint with the U.S. International Trade Commission, alleging that Angelalign Technology infringed on its patents by importing and selling unauthorized clear aligners in the United States.
• This move highlights Align’s ongoing legal campaign to safeguard its intellectual property and defend its leadership position in the global clear aligner industry.
• We'll assess how Align's legal action to block rival imports could alter its competitive outlook and investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Align Technology Investment Narrative Recap

To own Align Technology stock, you need to believe in the company's ability to defend its market-leading Invisalign brand through innovation, international expansion, and the protection of its intellectual property. The company’s recent Section 337 complaint against Angelalign Technology seeks to block a key competitor from importing allegedly infringing clear aligners, which could shape its competitive standing. However, in the short term, this legal action does not appear to materially change the main near-term catalyst: recovery in clear aligner demand amid macroeconomic headwinds, or the primary risk of sluggish patient traffic and shifting orthodontic preferences hurting revenue growth.

Among recent announcements, the launch of the Invisalign Palatal Expander System in India stands out. This product broadens Align’s international reach and clinical offerings, supporting efforts to grow its customer base and address demand softness through new innovations, even as the company’s legal and competitive challenges remain in focus.

Yet in contrast to Align’s global ambitions, investors should be aware that persistently weak orthodontic case starts and growing cost pressures could...

Align Technology's outlook anticipates $4.5 billion in revenue and $674.8 million in earnings by 2028. This scenario assumes 4.6% annual revenue growth and an increase in earnings of $237.2 million from the current $437.6 million.

Uncover how Align Technology's forecasts yield a $186.36 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Seven Simply Wall St Community members value Align shares between US$140 and US$320. Seven independent views reflect strong disagreement, with ongoing industry pressure and legal disputes affecting confidence in Align’s long-term earnings potential. Explore different perspectives to see how opinions compare.

Explore 7 other fair value estimates on Align Technology - why the stock might be worth over 2x more than the current price!

Build Your Own Align Technology Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Align Technology research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Align Technology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Align Technology's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.